Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling T Gronemeyer, C Chidley, A Juillerat, C Heinis, K Johnsson Protein Engineering, Design and Selection 19 (7), 309-316, 2006 | 201 | 2006 |
A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis C Chidley, H Haruki, MG Pedersen, E Muller, K Johnsson Nature Chemical Biology 7 (6), 375-383, 2011 | 147 | 2011 |
An enhanced isothermal amplification assay for viral detection J Qian, SA Boswell, C Chidley, Z Lu, ME Pettit, BL Gaudio, JM Fajnzylber, ... Nature Communications 11 (1), 5920, 2020 | 139 | 2020 |
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity AC Palmer, C Chidley, PK Sorger Elife 8, e50036, 2019 | 114 | 2019 |
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells L Gerosa, C Chidley, F Fröhlich, G Sanchez, SK Lim, J Muhlich, JY Chen, ... Cell Systems, 2020 | 100 | 2020 |
The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine C Chidley, SA Trauger, K Birsoy, EK O'Shea Elife 5, e14601, 2016 | 59 | 2016 |
A designed protein for the specific and covalent heteroconjugation of biomolecules C Chidley, K Mosiewicz, K Johnsson Bioconjugate chemistry 19 (9), 1753-1756, 2008 | 25 | 2008 |
A CRISPRi/a screening platform to study cellular nutrient transport in diverse microenvironments C Chidley, AM Darnell, BL Gaudio, EC Lien, AM Barbeau, ... Nature Cell Biology, 1-14, 2024 | 12 | 2024 |
Searching for the protein targets of bioactive molecules C Chidley, H Haruki, MG Pedersen, C Fellay, S Moser, K Johnsson Chimia 65 (9), 720-720, 2011 | 12 | 2011 |
Mutants of O6-alkylguanine-DNA alkyltransferase J Barnikow, C Chidley, T Gronemeyer, C Heinis, H Jaccard, K Johnsson, ... US Patent 7,888,090, 2011 | 11 | 2011 |
Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress BT Do, PP Hsu, SY Vermeulen, Z Wang, T Hirz, KL Abbott, N Aziz, ... Developmental Cell, 2024 | 7 | 2024 |
ASCT2 is the primary serine transporter in cancer cells KO Conger, C Chidley, ME Ozgurses, H Zhao, Y Kim, SE Semina, P Burns, ... bioRxiv, 2023 | 3 | 2023 |
A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy AC Palmer, C Chidley, PK Sorger bioRxiv 462184, 2019 | 2 | 2019 |
A Novel Yeast-Based Platform for Small Molecule Target Deconvolution Reveals Previously Unknown Binding Partners for the Approved Drugs Erlotinib, Atorvastatin, and Sulfasalazine C Chidley EPFL, 2010 | 2 | 2010 |
Method of Crosslinking Two Objects of Interest K Johnsson, C Chidley, K Mosiewicz US Patent App. 12/594,256, 2010 | 1 | 2010 |
ASCT2 is a major contributor to serine uptake in cancer cells KO Conger, C Chidley, ME Ozgurses, H Zhao, Y Kim, SE Semina, P Burns, ... Cell reports 43 (8), 2024 | | 2024 |
Abstract LB-B09: ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells L Gerosa, C Chidley, F Froehlich, G Sanchez, SK Lim, J Muhlich, JY Chen, ... Molecular Cancer Therapeutics 18 (12_Supplement), LB-B09-LB-B09, 2019 | | 2019 |
Compositions and use of sulfasalazine K Johnsson, C Chidley | | 2011 |
Directed molecular evolution of protein function C Chidley EPFL, 2005 | | 2005 |
LPPT V Baeriswyl, S Bellotto, M Bergeron-Brlek, D Bertoldo, MP Biedermann, ... | | |